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Editorial
Vascular Nox4
A Multifarious NADPH Oxidase
Rhian M. Touyz, Augusto C. Montezano
Nox4, one of the 7 isoforms of the NADPH (nicotinamideadenine dinucleotide phosphate) oxidase family that
generate reactive oxygen species, was first identified in the
early 2000s in kidneys.1 Nox4 was originally described as an
oxygen sensor and regulator of kidney cell growth and
because of its renal abundance was termed “renox.”1 It soon
became evident that Nox4 has a ubiquitous distribution and
that it is expressed in many organ systems, such as the
vasculature, and in many cell types including endothelial and
vascular smooth muscle cells and in adventitial fibroblasts
and adipocytes.2
Article, see p 1217
Nox4 is a unique Nox isoform. It localizes in the plasma
membrane as well as intracellularly (focal adhesions, nucleus,
mitochondria, endoplasmic reticulum), is constitutively ac-
tive, is regulated at the gene level, associates with novel
regulators such as Poldip2, and is influenced by vasoactive
agonists (angiotensin II), physical factors (shear stress and
flow), chemical changes (hypoxia), and microRNAs
(miRNA25).2–4 Nox4 associates with p22phox for its activa-
tion, does not require interaction with classic NADPH oxi-
dase cytosolic subunits (p47phox, p67phox, p40phox), and,
unlike other Noxs, generates H2O2 in preference to O2.2–4
Despite the fact that there has been enormous advancement in
the understanding of Nox4 biochemistry and the mechanisms
of Nox4 regulation, the functional significance and biological
role of Nox4 remain elusive. Most studies investigating the
(patho)physiology of Nox4 in the vascular system were
conducted in cell-based systems, and those performed in
animal studies were largely descriptive. Until very recently,
mice in which Nox4 gene was knocked out were not available
to study.
Fewer than 250 original papers with key words “Nox4”
and “Vascular” (PubMed search) have been published since
the identification of Nox4 in 2001, indicating that the field is
still immature with much to learn. Studies from cultured
vascular smooth muscle and endothelial cells demonstrated
that Nox4 is a pleitropic protein signaling through many
pathways with multiple functions including cell growth,
apoptosis, inflammation, differentiation, cytoskeletal remod-
eling, angiogenesis, and tumor growth.5,6 Animal and human
studies showed that expression of vascular Nox4 is increased
in numerous cardiovascular diseases, such as hypertension,
atherosclerosis, diabetes, restenosis, ischemia reperfusion
injury, fibrosis, vascular aging, and pulmonary hyperten-
sion.7,8 Collectively, these data implicate an important role
for Nox4 in physiological processes associated with cell
growth and differentiation and an injurious role in vascular
disease.
Supporting the harmful actions of Nox4 are reports that
pharmacological inhibition of Nox4, or partial gene knock-
down of Nox4, reverses or prevents Nox4-associated vascular
inflammation and remodeling.9,10 For example, in obese
Zucker rats, a model of obesity and insulin resistance,
common carotid injury was attenuated by Nox4 knockdown
with Nox4 short hairpin RNA, implicating Nox4 in neointi-
mal formation and vascular injury.10 Pharmacological inhib-
itors of Nox4 (VAS2870 and GKT136901) also prevented
agonist-induced oxidative stress and inflammatory responses
in cultured cells.11,12 However, these observations are merely
suggestive of Nox4 in vascular pathology and by no means
establish cause and effect.
Genetically modified mouse strains to investigate the roles
of Nox isoforms in experimental models of vascular disease
have been limited to Nox1 and Nox2.13 It is only very
recently that Nox4 transgenic and knockout mouse models
have become available, and the data deriving from such
models have yielded surprising results because, unexpect-
edly, and as demonstrated in the study by Schroder et al in the
current issue,14 it seems that Nox4 may in fact be vascular-
protective rather than vascular-damaging.
The first study investigating direct in vivo effects of Nox4
on vascular function was reported in 2011 by Ray et al,15 in
which gene-modified mice with endothelium-targeted Nox4
overexpression exhibited enhanced vasodilation and reduced
basal blood pressure. Key mechanisms underlying the vaso-
dilator effect of Nox4 were attributed to vasodilator effects of
increased H2O2 production and reduced NO inactivation. In
support of these findings, Schroder et al14 show that in global
Nox4 knockout mice, ischemia-induced angiogenesis is at-
tenuated and that in tamoxifen-inducible Nox4 knockout
mice, angiotensin II–mediated aortic inflammation, vascular
remodeling, and endothelial dysfunction are exaggerated,
effects associated with decreased eNOS expression, reduced
NO generation, and blunted heme oxygenase-1 expression. In
line with these data, others showed that in transgenic mice
with endothelial-specific Nox4 overexpression (VECad-
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Nox4 mice), recovery from hind limb ischemia was enhanced
with increased aortic capillary sprouting.16 Collectively, these
data suggest that endothelial Nox4 promotes angiogenesis
and recovery from hypoxia. Molecular mechanisms impli-
cated in Nox4 vasoprotection include activation of eNOS and
increased production of the vasodilator NO, generation of
H2O2, a putative endothelium-derived relaxing factor, and
increased expression/activation of antioxidant systems such
as Nrf-2, a master regulator of antioxidant genes. Hence,
based on these recent studies using Nox4 transgenic and
knockout mouse models, a new paradigm is emerging that
Nox4 may be vasculoprotective and that upregulation of this
Nox isoform may have potential therapeutic benefit in pre-
venting vascular disease.
However, data from Nox4/ mice are not consistent. In
models of transient or permanent stroke, Nox4-deficient mice
and mice treated with the Nox4 inhibitor VAS2870 were
protected from oxidative stress, blood-brain barrier leakage,
and neuronal apoptosis.17 These data suggest that Nox4 is a
major source of reactive oxygen species in ischemic stroke
and that inhibition of Nox4 may be a strategy for stroke
therapy.17
To reconcile the growing confusion in the field, a number
of considerations warrant further discussion. First, in the
study of Schroder et al,14 vascular functional studies were
performed in large conduit vessels (aorta) and in lung
endothelial cells from Nox4-deficient mice, whereas many
previous studies explored small arteries and cultured vascular
smooth muscle cells.3,5,9,10,11,17,18 Second, in Nox4 knockout
mice, the gene deletion is global, and, accordingly, it is not
entirely correct to implicate a vascular-specific pathology in
a model in which there is a ubiquitous knockout. Third, the
fact that it is only in challenged conditions that Nox4
knockout mice exhibit a vascular phenotype indicates a
nonessential role of Nox4 in physiological conditions. Fourth,
the experimental paradigms focused on ischemic injury and
angiotensin II–induced oxidative stress. It may be possible
that under diverse conditions of stress and challenge, regula-
tion of Nox4 may be very different, for example, angiotensin
II, ET-1, TGF, and stretch differentially regulate Nox4 in
vitro and in whole-animal studies.18,19 Fifth, recent evidence
indicates that Nox4 regulates its own expression. Overexpres-
sion of Nox4 in adventitial myofibroblasts inhibits endoge-
nous Nox4-mediated cell signaling, suggesting that Nox4
causes feedback inhibition of its own expression.20 Such
interactions may be important in mice in which Nox4 is
overexpressed, where Nox4 autoregulation of its own expres-
sion may affect vascular function and phenotype. Finally, the
experimental conditions in which Nox4 is genetically manip-
ulated must be considered because different approaches may
result in opposing outcomes. In fact, in some conditions, even
the same approach yields divergent results. Mice in which
Nox4 was targeted in a cardiac-specific manner demonstrated
that Nox4 is both protective21 and injurious22 in models of
cardiac overload.
The findings of Schroder et al14 and others15–17 certainly
challenge the dogma and are most thought-provoking. They
also highlight the need to understand why conclusions from
in vitro studies are opposite to those from in vivo studies and
why data from Nox4/ mice yield contradictory results.14–21
At the molecular level, the divergent effects may relate, at
least in part, to the relative proportion of H2O2 versus O2
produced (Figure). Further studies to elucidate the exact
(patho)physiological role of Nox4 are warranted, and, now
that Nox4 knockout mice and new tools to interrogate Nox4
are available for investigation, we should have a clearer
understanding of what Nox4 does in physiological and
pathological conditions. If future studies provide unambigu-
ous evidence that Nox4 is indeed vascular-protective, the
therapeutic potential of Nox4 inhibitors, which are currently
being developed for clinical use,23 comes under question
because such strategies may aggravate rather than ameliorate
vascular damage. There is thus an urgent need to unravel the
Nox4 paradox.
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